Navigation Links
New Vision Test Helps Detect Optic Nerve Diseases Including Glaucoma
Date:3/28/2011

PINE BROOK, N.J., March 28, 2011 /PRNewswire/ -- Diopsys, Inc. has launched the new Diopsys® NOVA-DN VEP Vision Testing System to help optometrists and ophthalmologists detect optic nerve disease, including glaucoma and other neuro-visual disorders.

Glaucoma is the second leading cause of blindness in the world, reports the World Health Organization. According to Prevent Blindness America, glaucoma is often called the "sneak thief of sight" because half of all patients who have it do not know it.  Many optic nerve disorders, such as glaucoma and ischemic optic neuropathy, are asymptomatic since central vision may not be affected until later stages of the disease. Also, diagnosis and management of optic nerve disorders are often based on structural or visual field tests which are limited in their ability to detect disease early.  

The Diopsys® NOVA-DN allows clinicians to objectively assess optic nerve disease earlier than traditional vision tests because it uses Visual Evoked Potential (VEP) technology and proprietary software to evaluate the entire vision system from the eye to the visual cortex. "VEP is an objective, functional test that can help discriminate between healthy and glaucomatous eyes," says Alberto Gonzalez Garcia, M.D., neuro-ophthalmologist and Research Director at Diopsys, Inc. Optometrists and ophthalmologists may use VEP in addition to traditional testing methods to enhance diagnosis and treatment.

The Diopsys® NOVA-DN records the electrical response of a patient's entire vision system and provides easy-to-read reports that give the doctor a simple way to evaluate optic nerve function.  Physicians are able to compare tests over time to track disease progression.

Dr. Fran Bucciero of Family Vision Care in Springfield, NJ, one of the first eye care professionals to have the device in his office says, "I've been using the Diopsys® NOVA-DN in my practice to help me diagnose glaucoma patients, and to track their disease progression. Because of the straightforward reports, I am able to show my patients how well their treatment is working which helps enormously with treatment compliance."  

Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care.  The company specializes in the development and marketing of patient-friendly, non-invasive diagnostic vision testing equipment.  Diopsys has developed and markets the patented Enfant® Pediatric Vision Testing System, a device used by pediatricians to test for visual deficits, including amblyopia, in children as young as six months of age. Diopsys also developed and markets the Diopsys® NOVA-DT (Diagnostic & Tracking), Diopsys® NOVA-TR (Transient Response) and Diopsys® NOVA-DN (Diseases of the Optic Nerve)  Vision Testing Systems utilized by ophthalmologists and optometrists for the detection, diagnosis and treatment of vision disorders.


'/>"/>
SOURCE Diopsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
2. CooperVision Introduces New Corporate Brand Identity
3. New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates Conflict of Interest
4. Erica L. Mann, Former Pfizer Executive, Appointed New President of Bayer HealthCares Global Consumer Care Division
5. TLC Vision Announces TLC Laser Eye Center San Diego
6. Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe
7. New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92%
8. Sevocity, a Division of Conceptual MindWorks, Incs Sevocity Receives ONC-ATCB 2011/2012 Certification
9. HealthWarehouse.com Acquires Online Division of Hocks Pharmacy
10. Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer
11. Elka Nir Joins VisionCare Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):